These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35668493)

  • 1. Association between the severity of metabolic dysfunction-associated fatty liver disease and the risk of colorectal neoplasm: a systematic review and meta-analysis.
    Zeng Y; Cao R; Tao Z; Gao Y
    Lipids Health Dis; 2022 Jun; 21(1):52. PubMed ID: 35668493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study.
    Fukunaga S; Nakano D; Kawaguchi T; Eslam M; Ouchi A; Nagata T; Kuroki H; Kawata H; Abe H; Nouno R; Kawaguchi K; George J; Mitsuyama K; Torimura T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34067258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Risk of Colorectal Adenoma in Nonalcoholic or Metabolic-Associated Fatty Liver Disease.
    Seo JY; Bae JH; Kwak MS; Yang JI; Chung SJ; Yim JY; Lim SH; Chung GE
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating chemerin levels in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
    Ren Q; Wang H; Zeng Y; Fang X; Wang M; Li D; Huang W; Xu Y
    Lipids Health Dis; 2022 Mar; 21(1):27. PubMed ID: 35236351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis.
    Ke Y; Liu S; Zhang Z; Hu J
    Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of circulating omentin level and metabolic-associated fatty liver disease: a systematic review and meta-analysis.
    Zhang Q; Chen S; Ke Y; Li Q; Shen C; Ruan Y; Wu K; Hu J; Liu S
    Front Endocrinol (Lausanne); 2023; 14():1073498. PubMed ID: 37139340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Associated Fatty Liver Disease Is Associated With an Increased Risk of Severe COVID-19: A Systematic Review With Meta-Analysis.
    Hegyi PJ; Váncsa S; Ocskay K; Dembrovszky F; Kiss S; Farkas N; Erőss B; Szakács Z; Hegyi P; Pár G
    Front Med (Lausanne); 2021; 8():626425. PubMed ID: 33777974
    [No Abstract]   [Full Text] [Related]  

  • 8. The Association of Metabolic-Associated Fatty Liver Disease with Clinical Outcomes of COVID-19: A Systematic Review and Meta-Analysis.
    Hayat U; Ashfaq MZ; Johnson L; Ford R; Wuthnow C; Kadado K; El Jurdi K; Okut H; Kilgore WR; Assi M; Siddiqui AA
    Kans J Med; 2022; 15():241-246. PubMed ID: 35899064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals.
    Chan KE; Koh TJL; Tang ASP; Quek J; Yong JN; Tay P; Tan DJH; Lim WH; Lin SY; Huang D; Chan M; Khoo CM; Chew NWS; Kaewdech A; Chamroonkul N; Dan YY; Noureddin M; Muthiah M; Eslam M; Ng CH
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2691-2700. PubMed ID: 35587339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease.
    Zhu C; Huang D; Ma H; Qian C; You H; Bu L; Qu S
    Front Endocrinol (Lausanne); 2022; 13():848937. PubMed ID: 35620390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study.
    Lee H; Lee HW; Kim SU; Chang Kim H
    Clin Transl Gastroenterol; 2022 Jan; 13(1):e00435. PubMed ID: 35080508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.
    Liu J; Ayada I; Zhang X; Wang L; Li Y; Wen T; Ma Z; Bruno MJ; de Knegt RJ; Cao W; Peppelenbosch MP; Ghanbari M; Li Z; Pan Q
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e573-e582. PubMed ID: 33618024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis.
    Liu J; Mu C; Li K; Luo H; Liu Y; Li Z
    Int J Public Health; 2021; 66():1604371. PubMed ID: 34690666
    [No Abstract]   [Full Text] [Related]  

  • 14. Remnant Cholesterol Predicts Long-term Mortality of Patients With Metabolic Dysfunction-associated Fatty Liver Disease.
    Huang H; Guo Y; Liu Z; Zeng Y; Chen Y; Xu C
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3295-e3303. PubMed ID: 35521833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: A prospective analysis.
    Liu S; Wang J; Wu S; Niu J; Zheng R; Bie L; Xin Z; Wang S; Lin H; Zhao Z; Wang T; Xu M; Lu J; Chen Y; Xu Y; Wang W; Ning G; Bi Y; Li M; Xu Y
    Metabolism; 2021 Jul; 120():154779. PubMed ID: 33895182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B.
    van Kleef LA; Choi HSJ; Brouwer WP; Hansen BE; Patel K; de Man RA; Janssen HLA; de Knegt RJ; Sonneveld MJ
    JHEP Rep; 2021 Oct; 3(5):100350. PubMed ID: 34557660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis.
    Mantovani A; Dauriz M; Byrne CD; Lonardo A; Zoppini G; Bonora E; Targher G
    Metabolism; 2018 Oct; 87():1-12. PubMed ID: 29935236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers.
    Liu Z; Lin C; Suo C; Zhao R; Jin L; Zhang T; Chen X
    Metabolism; 2022 Feb; 127():154955. PubMed ID: 34915036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAFLD and risk of CKD.
    Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
    Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.